Analysts Set BioLife Solutions, Inc. (NASDAQ:BLFS) Price Target at $32.00

BioLife Solutions, Inc. (NASDAQ:BLFS) has been given a consensus recommendation of “Moderate Buy” by the five research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $32.00.

A number of analysts have commented on BLFS shares. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of BioLife Solutions in a research report on Monday, December 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, January 21st. Northland Securities set a $34.00 price target on shares of BioLife Solutions in a research report on Monday, January 5th. UBS Group reaffirmed a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. Finally, Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd.

Insider Buying and Selling

In other BioLife Solutions news, insider Karen A. Foster sold 96,923 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $20.15, for a total transaction of $1,952,998.45. Following the sale, the insider owned 113,742 shares of the company’s stock, valued at approximately $2,291,901.30. This represents a 46.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 99,641 shares of company stock worth $2,009,000 over the last quarter. Corporate insiders own 2.20% of the company’s stock.

Institutional Trading of BioLife Solutions

A number of institutional investors have recently bought and sold shares of the company. Amalgamated Bank boosted its position in BioLife Solutions by 3.5% during the third quarter. Amalgamated Bank now owns 10,898 shares of the medical equipment provider’s stock valued at $278,000 after acquiring an additional 366 shares during the last quarter. Louisiana State Employees Retirement System boosted its position in BioLife Solutions by 2.9% during the third quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider’s stock valued at $454,000 after acquiring an additional 500 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of BioLife Solutions by 2.7% during the second quarter. The Manufacturers Life Insurance Company now owns 20,764 shares of the medical equipment provider’s stock valued at $447,000 after purchasing an additional 555 shares during the period. Isthmus Partners LLC raised its holdings in shares of BioLife Solutions by 0.5% during the fourth quarter. Isthmus Partners LLC now owns 138,393 shares of the medical equipment provider’s stock valued at $3,346,000 after purchasing an additional 622 shares during the period. Finally, Hantz Financial Services Inc. raised its holdings in shares of BioLife Solutions by 54.1% during the third quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock valued at $48,000 after purchasing an additional 659 shares during the period. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Stock Up 4.5%

Shares of BioLife Solutions stock opened at $21.19 on Monday. BioLife Solutions has a twelve month low of $17.86 and a twelve month high of $29.62. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -192.62 and a beta of 2.00. The company’s fifty day moving average is $20.61 and its 200 day moving average is $23.87.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.